Navigation überspringen
Universitätsbibliothek Heidelberg
Standort: ---
Exemplare: ---
heiBIB
 Online-Ressource
Verfasst von:Strobel, Sophia [VerfasserIn]   i
 Machiraju, Devayani [VerfasserIn]   i
 Kälber, Katharina [VerfasserIn]   i
 Hassel, Jessica C. [VerfasserIn]   i
Titel:Immune-related adverse events of COVID-19 vaccination in skin cancer patients receiving immune-checkpoint inhibitor treatment
Verf.angabe:Sophia B. Strobel, Devayani Machiraju, Katharina A. Kälber, Jessica C. Hassel
E-Jahr:2022
Jahr:23 December 2021
Jahr des Originals:2021
Umfang:6 S.
Fussnoten:Gesehen am 06.06.2023
Titel Quelle:Enthalten in: Cancer immunology immunotherapy
Ort Quelle:Berlin : Springer, 1976
Jahr Quelle:2022
Band/Heft Quelle:71(2022), 8, Seite 2051-2056
ISSN Quelle:1432-0851
Abstract:To date, few data are available regarding Adverse events (AEs) in cancer patients who are vaccinated for coronavirus disease 2019 (COVID-19) while being actively treated with Immune-checkpoint inhibitors (ICIs). We aimed to assess the safety of COVID-19 vaccines approved in Germany. Specifically, we investigated the frequency of general side effects and immune-related AEs of COVID-19 vaccination. A triage survey was used to collect the following information for patients with metastatic skin cancer: vaccine type, date of receipt of each dose of vaccine, and self-reported side effects. Clinical data were retrieved from the patients’ medical records. Of 130 patients with metastatic skin cancer, 89 patients were on immunotherapy and received COVID-19 vaccination. Of these 89 patients (median age: 64 years; 57 [64%] men), 89% had melanoma, and 71% received ICI therapy with a PD-1 antibody. Eighty-eight percent received an mRNA-based COVID-19 vaccination. The median follow-up time was 125 days after the first vaccination, and 84 days after the second. The most common observed side effects were mild to moderate pain at the injection site (40%), followed by fatigue (24%). Grade 3 irAEs were reported in eight patients, seven of whom were on nivolumab plus ipilimumab combination treatment. Of the 19 patients vaccinated within 72 h before/after ICI, five developed irAEs within 17 days (1-17 days). This small cohort study suggests that approved COVID-19 vaccinations are safe for use in cancer patients receiving ICIs. However, some precautions should be taken, especially regarding the timing of vaccination and ICI treatment.
DOI:doi:10.1007/s00262-021-03133-w
URL:kostenfrei: Volltext: https://doi.org/10.1007/s00262-021-03133-w
 DOI: https://doi.org/10.1007/s00262-021-03133-w
Datenträger:Online-Ressource
Sprache:eng
Sach-SW:Adverse events
 Cancer patients
 COVID-19 vaccination
 Immune-checkpoint inhibitors
K10plus-PPN:1847534716
Verknüpfungen:→ Zeitschrift
 
 
Lokale URL UB: Zum Volltext

Permanenter Link auf diesen Titel (bookmarkfähig):  https://katalog.ub.uni-heidelberg.de/titel/69082956   QR-Code
zum Seitenanfang